Unknown

Dataset Information

0

Panel-based next-generation sequencing facilitates the characterization of childhood acute myeloid leukemia in clinical settings.


ABSTRACT: Acute myeloid leukemia (AML) accounts for ~20% of pediatric leukemia cases. The prognosis of pediatric AML has been improved in recent decades, but it trails that of most other types of pediatric cancer, with mortality rates of 30-40%. Consequently, newer more targeted drugs are required for incorporation into treatment plans. These newer drugs selectively target AML cells with specific gene alterations. However, there are significant differences in genetic alterations between adult and pediatric patients with AML. In the present study, inexpensive and rapid next-generation sequencing (NGS) of >150 cancer-related genes was performed for matched diagnostic, remission and relapse (if any) samples from 27 pediatric patients with AML. In this analysis, seven genes were recurrently mutated. KRAS was mutated in seven patients, NRAS was mutated in three patients, and KIT, GATA1, WT1, PTPN11, JAK3 and FLT3 were each mutated in two patients. Among patients with relapsed AML, six harbored KRAS mutations at diagnosis; however, four of these patients lost these mutations at relapse. Additionally, two genetic alterations (FLT3-ITD and TP53 alterations) were detected among patients who eventually relapsed, and these mutations are reported to be adverse prognostic factors for adult patients with AML. This panel-based, targeted sequencing approach may be useful in determining the genetic background of pediatric AML and improving the prediction of treatment response and detection of potentially targetable gene alterations. RAS pathway mutations were highly unstable at relapse; therefore, these mutations should be chosen as a target with caution. Incorporating this panel-based NGS approach into the clinical setting may allow for a patient-oriented strategy of precision treatment for childhood AML.

SUBMITTER: Ishida H 

PROVIDER: S-EPMC7469563 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Panel-based next-generation sequencing facilitates the characterization of childhood acute myeloid leukemia in clinical settings.

Ishida Hisashi H   Iguchi Akihiro A   Aoe Michinori M   Nishiuchi Ritsuo R   Matsubara Takehiro T   Keino Dai D   Sanada Masashi M   Shimada Akira A  

Biomedical reports 20200828 5


Acute myeloid leukemia (AML) accounts for ~20% of pediatric leukemia cases. The prognosis of pediatric AML has been improved in recent decades, but it trails that of most other types of pediatric cancer, with mortality rates of 30-40%. Consequently, newer more targeted drugs are required for incorporation into treatment plans. These newer drugs selectively target AML cells with specific gene alterations. However, there are significant differences in genetic alterations between adult and pediatri  ...[more]

Similar Datasets

| S-EPMC6355503 | biostudies-literature
| S-EPMC10248931 | biostudies-literature
| S-EPMC3364462 | biostudies-literature
| S-EPMC10002321 | biostudies-literature
| S-EPMC8514876 | biostudies-literature
| S-EPMC4201902 | biostudies-literature
| S-EPMC6518900 | biostudies-literature
| S-EPMC8102181 | biostudies-literature
| S-EPMC9776673 | biostudies-literature
| S-EPMC8869405 | biostudies-literature